UBP 302

Key Product Details

Product Description

UBP 302 is a potent and selective GluK1 (formally GluR5)-subunit containing kainate receptor antagonist (apparent K_D = 402 nM); active enantiomer of UBP 296 (Cat. No. 2078). Displays ~ 260-fold selectivity over AMPA receptors, ~ 90-fold selectivity over recombinant human GluK2 (formally GluR6) and GluK5 (formally KA2)-containing kainate receptors and has little or no action at NMDA or group I mGlu receptors. Selectively blocks kainate receptor-mediated LTP induction in rat hippocampal mossy fibers. Also protects against soman-induced seizures and neuronal degeneration for up to 30 days when administered one hour after soman exposure.

Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.

Product Specifications for UBP 302

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for UBP 302

The following data is based on the product molecular weight 333.30.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

6 5 4 3 2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.25 mM	12.00 mL	60.01 mL	120.01 mL
1.25 mM	2.40 mL	12.00 mL	24.00 mL
2.5 mM	1.20 mL	6.00 mL	12.00 mL
12.5 mM	0.24 mL	1.20 mL	2.40 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 40 publications citing the usage of this product.

• Dolman Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors. J.Med.Chem. 2005 PMID: 16302825
• Apland The Limitations of D.pam as a Treatment for Nerve Agent-Induced Seizures and Neuropathology in Rats: Comparison with UBP302. J.Pharmacol.Exp.Ther. 2014 PMID: 25157087
• More Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist. Neuropharmacology 2004 PMID: 15165833

Product Documents for UBP 302